throbber
VOLUME 43' NO. ZCNREABO PP 4815933
`2“February 1985
`
`
`
`u n- -
`
`BIOEPIS EX. 1106
`
`Page 1
`
`BIOEPIS EX. 1106
`Page 1
`
`

`

`Notice to Members of the American Association lor Cancer Research
`
`Offtcers for 7984-7985
`'
`President: Isaiah J. Fidler, M . D. Anderson Hospital and l;urnor Institute, Te.<as Medical Center, P. 0. Box HMB-173, Houston, Texas 77030
`Vice President: Arthur B. Pardee. Dana-Farber Cancer Institute. 44 Binney Street. Boston. Mass. 02 115.
`Secretary-Treasurer: Robert E. Handschumacher. Yale University School of Medicine, 333 Cedar Street. New Haven. Connecticut 06510
`Executive Director: Margaret Foti, Temple University SchOOl of Medicine. West Building. Room 301 . Philadelphia, Pa. 19140
`
`Annual Dues
`The annual dues of active members of the American Association lor Cancer Research are $75.00 and they include a subscription to the journal Cancer Research. The
`regular subscription price of Cancer Research for members of the Association is $50.00 per annual volume. Corresponding members of the AsSOCiation should add
`$30.00 to this rate to offset postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to the office of the
`American Association for Cancer Research, cto Margaret Foti, Executive Director. American Association for Cancer Research, Temple University School of Medicine.
`West Building. Room 301. Philadelphia. Pa. 19140 (215-221-4565).
`
`Back Issues and Single Copy Sales of the Journal
`Copies of back stock of the journal· Cancer Research may be ordered from Waverty Press. Inc. As long as supplies permit, single copies of Cancer Research will be
`sold by this company at $20.00 per copy for regular issues and $20.00 per copy for Supplement issues which contain material from conferences on topics related to
`cancer. The annual Proceedings of the American Association lor Cancer Research is available at $20.00 per copy.
`
`Advertisements in Cancer Research
`Advertisement insertion orders and copy must be received 60 days prior to the month of issue in which the advertisement is to be published. The journal is mailed on
`or about the 20th of the month preceding the month of issue. Inquiries about advertising should be directed to: Donald H. Nichols, Vice Presiclent, Journal Sales. Waverly
`Press. Inc .. 428 E. Preston Street. Baltimore. Maryland 21202. Telephone: 301/528-4280.
`
`Historical Cover Themes
`Readers are invited to submit themes (events, persons, Institutions) lor consicleration for the illustrated covers of Cancer Research. Correspondence regard1ng
`suggested cover themes, or other matters regarding covers, should be addressed to the Cover Editor. Cancer Research Editorial OffiCe.
`
`Submission of Manuscripts
`Papers submitted for publication in Cancer Research and all other communications for the attention of the Editor should be sent to: Dr. Peter N. Magee. Editor, Cancer
`Research, Feis Research Institute. Temple University SchOOl of Medicine, Philadelphia, Pennsylvania 19 140. Telephone: 215/221-4720. Cancer Research publishes
`original studies in all the sublields of cancer research, including: biochemistry and physiology; chemical and physical carcinogenesis and mutagenesis; clinical investigations;
`endocrinology; epiclemiology and biostatiSticS; immunology; molecular and cell biology; preclinical pharmacology and experimental therapeutics; radiobiology; and virology.
`C~nical investigations and epidemiological studies are published in a separate section from papers in the basic sciences. Authors should consult the detailed " Instructions
`for Authors" printed in the January issue of the journal. copies of which are available upon request.
`
`Manuscript Processing Fee
`Journal policy requires that a manuscript processing fee of $75.00 be assessed for each paper to defray the expenses incurred in the editorial review process. An
`invoice is sent to the author upon receipt of the manuscript . Review to determine acceptability will not be delayed pending payment of this fee.
`
`Copyright and Copyright Clearance Center
`The Copyriight Revision Act (PL 94-553), which became effective January 1. 1978, states that the copyriight of a work is vested in the author from the moment of
`creation. Therefore, all authors who wish to publish in Cancer Research must formally transfer copyriight to the proprietor of the journal, Cancer Research, Inc. It 1s
`understood by this transfer that the authors relinquish all exclusive riights of oopyriight ownership, including the riights of reproduction, derivation, distribution, sale,
`and display.
`Authors who prepared their articles as part of their official duties as emplOyees of the U. S. F.ederal Government are not required to transfer copyriight to Cancer
`Research. Inc .. since these articles are considered to be in the public domain. However, it is necessary lor these authors to sign the appropriate section of the transfer
`form. In the case of articles supported by federal grants or contracts, copyright transfer to Cancer Research, Inc., is required. The federal government may retain a
`nonexclusive license to publish or republish such material.
`The duly authorized agent of a commercial form or commissioning organizatton must sign the transfer form if the author prepared the article as part of his or her
`offiCial duties as an employee.
`,
`Appropriate forms for transfer of copyright will be sent routinely with acknowledgment of receipt of manuscripts for review .'They may also be requested from the
`Cancer Research Editorial Office. The journal will not publish a paper unless the form is property completed and signed.
`Copies of articles for w hich Cancer Research owns the copyright may be made lor personal or internal use, provicled that the copier pay the per-<:opy fee of $2 00
`through the Copyright Clearance Center, Inc. This Center is a nonprofit organization through which individuals and institutions may reimburse a copyriight owner for
`photocopying journal articles beyond what is defined as " fair use" in Sections 107 and 108 of the Copyriight Revision Act of 1978.
`Those who wish to photocopy Cancer Research articles may report the number of copies they have made. together with the lee code 0008-5472/85 $02.00. to:
`Copyriight Clearance Center, Inc., 21 Congress St .. Salem, Mass. 01970. Remittances may be sent to the Center at the time of reporting or the Center will bill the
`user on a monthly basis. Deposit accounts and prepayment plans may also be arranged.
`Between June 1 978 and August 1983. a fee code appeared on the first page of all articles lor which Cancer Research owned the copyright. For those issues. •t 1S
`understood that any articles which did not carry this code are in the public domain.
`
`Cancer Research is abstracted or indexed in Biological Abstracts, Chemical Abstracts, Index Medicus, Science Citation Index, and by the International Cancer Research
`Data Bank.
`
`No responsibility is accepted by the Editors, by Cancer Research, Inc., by the American Association lor Cancer Research, tnc., or by Waverty Press, Inc. l or the
`opinions expressed by contributors or for the content of the advertisements.
`
`Cancer Research (ISSN 0008-5472) is published monthly lor $50 per year (for members of the American Association for Cancer Research) or $100 and $175 per year
`(for nonmembers) by Cancer Research, Inc. Second-class postage paid at Baltimore. Md. and additional mailing olftces. POSTMASTER: Send address changes to
`Cancer Research, c/o Waverty Press. Inc .• 428 E. Preston Street. Baltimore, Md. 21202.
`
`Copyriight 1985 by Cancer Research. Inc.
`
`BIOEPIS EX. 1106
`Page 2
`
`

`

`[CANCER RESEARCH 45. 879-885, February 19851
`
`:-tuman Anti-Murine Immunoglobulin Responses in Patients Receiving
`~VIonoclonal Antibody Therapy 1
`
`i lobert W. Schr.off,2 Kenneth A. Foon, Shannon M. Beatty, Robert K. Oldham, and Alton C. Morgan, Jr.
`
`,Jiological Therapeutics Branch, Biological Response Modiliers Program. National Cancer Institute, Frederick, Maryland 21701
`
`, BSTRACT
`
`Human anti-murine immunoglobulin responses were assessed
`in serum from three groups of patients receiving murine mono(cid:173)
`clonal antibody therapy. Each of the three patient groups re(cid:173)
`sponded differently. Chronic lymphocytic leukemia patients dem(cid:173)
`onstrated little or no preexisting murine immunoglobulin G-reac(cid:173)
`tive antiglobulin prior to treatment, while the cutaneous T-cell
`lymphoma and melanoma patients demonstrated preexisting
`antiglobulin levels in the same range as those demonstrated in
`healthy controls. None of 11 chrqnic lymphocytic leukemia pa(cid:173)
`tients receiving the T1 01 monoclonal antibody demonstrated an
`antiglobulin response, whereas all four of the cutaneous T-cell
`lymphoma patients receiving the same antibody developed in(cid:173)
`creased levels of antiglobulins. Three of nine malignant mela(cid:173)
`noma patients receiving the 9.2.27 monoclonal antibody showed
`an increase in antiglobulin titers. In patients developing antiglob(cid:173)
`ulin responses, the response was rapid, typically being detect(cid:173)
`able within 2 weeks. The antiglobulins were primarily immuno(cid:173)
`globulin G and, with the exception of a single melanoma patient
`in whom the response appeared to have a substantial 9.2.27-
`specific component (i.e., antiidiotype), were cross-reactive with
`most murine immunoglobulin G preparations tested. This pattern
`of results suggested that the antiglobulin was a secondary
`immune reaction with elevation of the levels of preexisting anti(cid:173)
`globulin which was cross-reactive with the mouse antibody ad(cid:173)
`ministered. While the presence of serum antiglobulin would be
`expected to present major complications to monoclonal antibody
`therapy, no clinical toxicity related to antiglobulin responses was
`observed in these patients, and no inhibition of antibody localiza(cid:173)
`tion on tumor cells was seen.
`
`INTRODUCTION
`
`Attempts at serotherapy of human tumors date back to the
`treatment of chronic myelogenous leukemia with antisera by
`Lindstrom (6) in 1927. However, due to the difficulty in obtaining
`large quantities of antisera of sufficient specificity, and the many
`side effects of crude antisera, this form of therapy has not come
`into general use. The development of monoclonal antibodies of
`defined specificity and unlimited availability has rekindled interest
`in the use of passively administered antibody as a form of cancer
`therapy (13).
`The development of host antibodies against passively admin(cid:173)
`istered immunoglobulin, with possible neutralization of the ad(cid:173)
`ministered immunoglobulin and anaphylactic or other immune
`
`' This project has been funded at least in part with Federal funds from the
`Department of Health and Human Services. under Contract NOt-C0-23910 with
`Program Resources, Inc.
`2 To whom requests for reprints should be addressed. at BRMP, NCI-FCRF,
`Bldg. 560, Room 31-93, Frederick, MD 21 701.
`Received February 17, 1984; accepted November 2, 1984.
`
`reactions, has been viewed as a potential major complication to
`serotherapy. Recent reports of clinical trials with murine mono(cid:173)
`clonal antibodies have confirmed that human anti-mouse im(cid:173)
`munoglobulin antibodies may be induced (1 , 2, 10, 14, 17). Miller
`et at. (1 0) reported development of anti-mouse immunoglobulin
`antibodies in 4 of 7 T -cell lymphoma patients treated with the
`anti-Leu-1 monoclonal antibody. In 3 of these 4 patients, the
`development of anti-mouse immunoglobulin antibodies appeared
`to contribute to tumor escape from therapy. Similarly, Dillman et
`at. (1) attributed the lack of response to therapy, in 2 of 4
`cutaneous T-cell lymphoma patients receiving the T101 mono(cid:173)
`clonal antibody, to the presence of human anti-mouse immuno(cid:173)
`globulin antibodies. Sears et at. (17) also reported the presence
`of human anti-mouse immunoglobulin antibodies in 9 of 18
`gastrointestinal tumor patients receiving the monoclonal antibody
`1083-17-1A. However, other studies did not report that human
`antiglobulin responses presented major problems in monoclonal
`antibody therapy (3, 7-9, 15). The relatively small number of
`reports in the literature of monoclonal antibody clinical trials, the
`variety of diseases treated, and the lack of uniformity in the
`design of these trials makes it difficult to draw general conclu(cid:173)
`sions as to the conditions under which host anti-mouse immuno(cid:173)
`globulin responses would be expected to develop.
`The Biological Therapeutics Branch of the National Cancer
`Institute has recently completed Phase I clinical trials with the
`lgG2a monoclonal antibody T1 01 in patients with CLL 3 and CTCL
`and the lgG2a monoclonal antibody 9.2.27 in patients with
`malignant melanoma (2, 3, 14). The T1 01 antibody recognizes
`the T65 antigen present on the cell surface of both normal and
`malignant T -cells, as well as some B-cell cancers, including CLL
`(16). The 9.2.27 antibody recognizes aM, 250,000 glycoprotein(cid:173)
`proteoglycan associated with melanoma (11 ). In this paper, the
`host anti-mouse immunoglobulin responses observed during
`these trials are summarized, with a comparison of the differences
`and similarities in the responses elicited within the 3 disease
`groups, and an analysis of the specificity of the detected anti(cid:173)
`bodies.
`
`MATERIALS AND METHODS
`
`Patients. Patients considered for the clinical trial with T1 01 were
`adults with histologically confirmed diagnosis of CLL or CTCL. Patients
`with malignant melanoma were considered as candidates for treatment
`with the 9.2.27 antibody. Patients received no radiation or immunosup(cid:173)
`pressive drugs for at least 4 weeks prior to entry into these trials. Prior
`to treatment, all patients were fully ambulatory and had no serious
`unrelated disease, and their tumor cells were positive for reactivity with
`the antibody to be used in therapy. The mean and range of age of each
`patient population was: CLL. 59, 43 to 81 ; CTCL, 56, 42 to 68; mela(cid:173)
`noma, 48, 23 to 72 years.
`
`3 The abbreviations used are: CLL, chronic lymphocytic leukemia; CTCL, cuta·
`neous T -cell lymphoma: ELISA. enzyme-linked immunosorbent assay.
`
`CANCER RESEARCH VOL. 45 FEBRUARY 1985
`879
`
`BIOEPIS EX. 1106
`Page 3
`
`

`

`HUMAN ANTI-MURINE IMMUNOGLOBULIN RESPONSES
`
`The control population used in this study consisted of 11 healthy
`individuals with no history of cancers and no previous therapy with
`murine-derived agents and ranged in age from 20 to 45 years, with a
`mean of 31 years .
`Study Plan. Patients were treated with either T1 01 or 9.2.27 mono(cid:173)
`clonal antibody. Details of the design and clinical findings of each trial
`have been reported elsewhere (3, 14). Briefly, patients with CLL or CTCL
`received T1 01 antibody i.v. at fixed-dose levels of 1, 10, 50, or 100 mg.
`Patients were treated twice weekly for 4 weeks. Initially, patients received
`the total dose of antibody.in 100 ml of 0.9% NaCI solution (saline) with
`,5% human albumin over 2 hr. Due to pulmonary toxicity associated with
`the rapid rate of infusion, this was later amended so that antibody was
`administered at a rate of no more than 1 to 2 mg of T1 01 antibody per
`hr. Melanoma patients received the 9.2.27 antibody by i.v. infusion in
`100 ml of saline with 5% human serum albumin over 2 hr. Each patient
`received single doses of antibody twice weekly on an .escalating dose
`schedule of 1' 10, 50, 100, and 200 mg or 10, 50, 100, 200, and 500
`mg. A summary of the number of patients treated and the amount of
`antibody administered is presented in Table 1.
`Assay for Human Anti-Mouse Antibody. Sera used in all assays
`were separated from peripheral blood and stQred at -20° until use.
`Antiglobulins in dilutions of serum were measured using solid-phase
`T101 or 9.2.27 antibodies dried at 37° overnight onto i>elyvinyl plates at
`100 ng of antibody per well and washed with 0.1 M tris (pH 8.3)-0.02%
`NaN3-0.5% Tween 20 (Sigma Chemical Co., St. Louis , MO). Dilutions of
`serum were incubated on the plates at room temperature for 45 min.
`Bound human immunoglobulin was detected with heavy chain-specific
`(-y or JJ.) goat anti-human immunoglobulin conjugated with alkaline phos(cid:173)
`phatase (Sigma) during a 45-min incubation. For comparison, standard
`curves were generated against solid-phase human lgM myeloma proteins
`or pooled normal human lgG (Cappel Laboratories, Cochranville, PA),
`and antiglobulin expressed as JJ.g of protein bound to plates per ml of
`serum.
`For assays of antiglobulin specificity, plates were coated with T1 01
`Fab or 9.2.27 F(ab' )2 preparations (100 ngfwell); the mouse myeloma
`proteins MOPC-21 (lgG1 ), RPC-5 (lgG2a), UPC-1 0 (lgG2a), MOPC-141
`(lgG2b), and FLOPC-21 (lgG3) (Litton Bionetics, Kensington , MD); mouse
`lgG (Sigma); mouse lgM (Pel Freeze Biologicals, Rogers, AR); rabbit lgG
`(Dako. Denmark); or whole T101 or 9.2.27 antibodies. Inhibition of
`binding to T1 01 or 9.2 .27 target antigen was assessed by performing
`the ELISA in the presence of a 1 000-fold-greater concentration (1 00 11g!
`well) of the soluble inhibitor murine lgG2a antibodies 9.2.27 , T1 01, D3,
`or RPC-5 as compared to the solid-phase target immunoglobulin.
`Assay for Mouse Immunoglobulin. Murine immunoglobulin in dilu(cid:173)
`tions of serum was assayed using affinity-purified goat anti-mouse
`immunoglobulin (KPL, Gaithersburg, MD) adsorbed onto polyvinyl plates
`at 1 00 ngfwell and washed as above. Bound mouse immunoglobulin
`
`Table 1
`Summary of monoclonal antibody therapy
`
`No. of patients
`treated
`
`1
`2
`1
`2
`1
`1
`2
`
`Disease
`CLL
`CLL
`CLL
`CLL
`CLL
`CLL
`CLL
`
`CICL
`CTCL
`CTCL
`CTCL
`
`Melanoma
`Melanoma
`
`Total dose
`received
`(mg)
`
`6
`8
`50
`80
`150
`300
`400
`
`8
`66
`80
`162
`
`361
`860
`
`was detected with a goat anti-mouse immunoglobulin conjugated with
`alkaline phosphatase (Sigma) and compared against a standard curve of
`either T1 01 or 9.2.27 antibody.
`Assay for Human Serum Immunoglobulin. Serum lgG and lgM levels
`were determined by radial immunodiffusion utilizing Endoplate immuno(cid:173)
`globulin test kits obtained from Kallestad Laboratories, Austin , TX .
`Immunofluorescent Staining of Melanoma Specimens. Tumor cells
`were prepared as single-cell suspensions by teasing tissues which were
`obtained from skin lesions. To assess in vivo localization of the murine
`9.2.27 antibody, the cell suspensions were incubated with fluorescein
`isothiocyanate-conjugated goat anti-mouse lgG (Tago, Inc. , Burlingame,
`CA) for 30 min at 4 ° . The cells were then washed by centrifugation and
`analyzed on a Cytofluorograf 50H (Ortho Diagnostic Systems, West(cid:173)
`wood, MA). A similar goat antibody directed against mouse lgM (Tago)
`was used as a negative control, and incubation in the presence of excess
`9.2.27 antibody served as a positive control. All biopsy specimens were
`obtained 24 hr following infusion of the 9.2.27 antibody.
`Statistical Evaluation. Serum antiglobulin levels for a given patient
`were considered significantly increased at antiglobulin levels greater than
`2 S.D.s above the mean of the healthy control group.
`
`RESULTS
`
`Development of Antiglobulin Responses. In order to deter(cid:173)
`mine the level of mouse-reactive antiglobulins which could be
`detected in healthy individuals by our ELISA, antiglobulin levels
`were assessed in 11 normal donors. As illustrated in Chart 1,
`the control population demonstrated detectable levels of lgG and
`lgM antiglobulin reactive with both the T1 01 and 9.2.27 antibod(cid:173)
`ies. These preexisting antiglobulin levels in the CLL patients prior
`to therapy were significantly lower (p < 0.005 by Student's t
`test) than those demonstrated by the healthy controls. Serurn
`immunoglobulin levels were determined on the same specimens.
`Both serum lgG and lgM levels were significantly lower in the
`CLL group as compared to the control group. However, CLL
`serum immunoglobulin levels were roughly one half that of con(cid:173)
`trols, while CLL antiglobulin levels were less than one tenth that
`of control antiglobulin levels.
`To substantiate that the assay used was in fact detecting
`human anti-mouse immunoglobulin antibody, 2 control experi(cid:173)
`ments were performed. To demonstrate that the binding of
`human immunoglobulin to the ELISA plate was not nonspecific,
`control and patient specimens were inclfbated on plates coated
`with either the T1 01 or 9.2.27 antibodies, or left uncoated. Table
`2 demonstrates that binding did not occur in the absence of
`mouse immunoglobulin on the plates and that binding was
`roughly equivalent irrespective of the antibody used to coat the
`plates. To further substantiate that the preexisting human anti(cid:173)
`body activity was indeed reactive with mouse immunoglobulin ,
`we performed the ELISA for human anti-mouse immunoglobulin
`activity in the presence of a 1 000-fold-greater concentration of
`a variety of murine lgG2a preparations. As indicated in Table 3,
`roughly 50% of the activity could be inhibited in such a manner.
`The percentage of inhibition represents the decrease in titer due
`to the presence of the inhibitor immunoglobulin. While there was
`substantial variability between titers of antiglobulin in the 5
`individuals examined, the percentage of inhibition in each case
`was quite similar, as indicated by the relatively low S.D. The
`inhibition was not restricted to the mouse immunoglobulin prep(cid:173)
`aration used as the solid-phase antigen. The remaining 50% of
`the activity is most likely attributable to the weak affinity of
`antiglobulins for soluble immunoglobulin (12) as compared to the
`
`CANCER RESEARCH VOL. 45 FEBRUARY 1985
`880
`
`BIOEPIS EX. 1106
`Page 4
`
`

`

`HUMAN ANTI-MURINE IMMUNOGLOBULIN RESPONSES
`
`Table 3
`Inhibition of 9.2.27-reactive human antiglobulin activity in normal human serum
`with murine lgG2a
`Values represent the mean of 5 healthy control specimens .
`
`1600
`
`1400
`
`........
`1200 a,
`'6
`g
`1000 C/)
`Qi
`>
`800 ~
`
`0
`600 SF
`E
`400 2
`<ll
`Vl
`
`200
`
`280
`
`240 ........
`~
`200 Ol g
`
`T101 9.2.27
`CONTROLS
`
`CLL
`
`CTCL
`
`lolol
`
`120
`
`C/)
`160 Qj
`>
`<ll
`...J
`:::l:
`SF
`80 E
`:J
`....
`Q)
`Vl
`
`40
`
`........
`
`10 B
`~ Ol
`2:
`
`8
`
`6
`
`4
`
`C/)
`Qj
`>
`Q)
`...J
`
`.0
`0
`
`,!;; -s
`:Q> c <
`
`E 2
`:J
`....
`Q)
`Vl
`
`lolo l
`
`CLL
`
`CTCL
`
`T101 9.2.27
`CONTROLS
`Chart 1 . Antiglobulin and serum immunoglobulin levels in healthy controls and
`patients prior to therapy. Serum lgG (A) or lgM (8 ) antibody levels to both T101
`and 9.2.27 antibodies in controls and the appropriate treatment antibody in patients
`IT1 01 for CLL and CTCL patients, 9.2.27 for melanoma (Mel ) patients] are shown
`(0 ). Serum immunoglobulin levels are indicated for comparison (•). Columns , mean
`of each group; bars , S.D . The number of individuals in each group was: control ,
`11 ; CLL, 11 ; CTCL. 4; melanoma, 9. ·, levels in patient groups which were
`significantly lower than those of the appropriate control group (p < 0.005 as
`determined by the Student t test).
`
`Table2
`Specific binding of human serum immunoglobulin in solid-phase ELISA lgG
`antiglobulin assay
`
`Serum specimen
`
`Melanoma Patient K. G.
`prior to 9.2.27 treat-
`ment
`
`Melanoma Patient K. G.
`following 9.2.27 treat-
`ment
`
`Normal control
`
`Solid-
`phase
`target
`antigen
`
`None•
`T101
`9.2.27
`
`None
`T101
`9.2.27
`
`None
`T1 01
`9.2.27
`
`Serum dilution
`
`1:10
`
`0.07b
`0.55
`0.47
`
`0.04
`0.56
`0.53
`
`0.08
`0.64
`0.70
`
`1:50
`
`0.00
`0.33
`0.31
`
`0.00
`0.43
`0.49
`
`0.00
`0.35
`0.37
`
`1:250
`
`1:1250
`
`0.00
`0.26
`0.24
`
`0.00
`0.42
`0.41
`
`0.00
`0.30
`0.25
`
`0.00
`0.14
`0.11
`
`0.00
`0.19
`0.20
`
`0.00
`0.10
`0.09
`
`• No target antigen or control protein bound to plates.
`b Mean of duplicate absorbance determinations at 405 nm.
`
`solid-phase immunoglobulin, or to nonspecific interactions (4)
`such as Fe-Fe interactions between the human immunoglobulin
`and solid-phase murine immunoglobulin.
`Antiglobulin levels were assessed in patients over the period
`of treatment with either T1 01 or 9.2.27 antibodies as the target
`
`Monoclonal
`antibodies
`
`None
`9.2.27
`T101
`03
`APC-5
`
`Inhibitor
`
`% of inhibition
`
`Titer"
`70 ± 45b
`42 ± 30
`42 ± 5
`43 ± 36
`41 ± 9
`34 ± 27
`51 ± 10
`35 ± 36
`57 + 17
`: Reciprocal of the dilution yielding an absorbance at 405 nm of 0.3.
`Mean± S.D.
`
`antigens. In the T1 01 trial , serum specimens were obtained
`before the third, fifth , and seventh doses. These specimens were
`obtained immediately prior to doses in order to minimize the
`possibility of circulating free mouse lgG being present in the
`specimen. To confirm that serum mouse lgG levels were low,
`mouse lgG levels were quantitated in all serum samples. Speci(cid:173)
`mens from CLL and CTCL patients all demonstrated mouse lgG
`levels of less than 1 JLg/ml. Specimens from melanoma patients
`demonstrated somewhat higher levels of mouse lgG but, in all
`cases , were less than 25 JLg/ml. As depicted in Chart 2, CLL
`patients treated with T1 01 failed to develop detectable antiglob(cid:173)
`ulin levels over the period of therapy. In contrast, while CTCL
`patients demonstrated rather low antiglobulin levels prior to
`receiving T1 01 antibody, a significant increase in lgG levels of
`antiglobulin developed over the course of therapy in all 4 patients
`(Chart 3). Three of these 4 patients also demonstrated rises in
`lgM antiglobulin levels over the course of therapy, but not to the
`same magnitude as lgG responses.
`Of the 9 melanoma patients in the 9.2.27 trial , 3 developed
`significant levels of lgG antiglobulin (Chart 4). These same 3
`patients demonstrated lower, but yet significant, levels of lgM
`antiglobulin during the course of therapy. All 3 individuals who
`developed antiglobulin levels received a total of 361 mg of 9.2.27
`antibody.

`Specificity of Antiglobulin Response. In order to determine
`the specificity of the antiglobulin responses elicited, sera from
`patients who demonstrated significant elevations in antiglobulin
`levels were tested against a variety of immunoglobulins (Table
`4). Specimens from th~ 4 CTCL patients were assessed for
`reactivity against whole T1 01 and a Fab fragment of T1 01 , as
`well as 5 lgG murine myeloma proteins, the lgG and lgM com(cid:173)
`ponents of normal mouse serum, and a rabbit lgG preparation.
`Specimens from the 3 melanoma patients who demonstrated
`antiglobulin responses were tested against a similar panel, with
`the exception that the F(ab ' )2 fragment of 9.2.27 was substituted
`for the Fab fragment of T1 01 .
`Sera from all 4 CTCL patients and the 3 melanoma patients
`demonstrated substantial reactivity with whole T1 01 or 9.2.27,
`most murine myeloma proteins of the different lgG subclasses,
`and mouse lgG (Table 4). Little or no reactivity was observed
`against the Fab or F(ab' )2 fragments or to mouse lgM. These
`results suggest that the antiglobulin response elicited in these
`patients was directed to determinants common to murine lgG
`and was not specific for either the T101 or 9.2.27 antibody.
`Further, the lack of reactivity to Fab or F(ab')2 fragments sug(cid:173)
`gests that the reactivity is directed against determinants on the
`Fe region of the immunoglobulin molecule and not determinants,
`
`CANCER RESEARCH VOL. 45 FEBRUARY 1985
`881
`
`BIOEPIS EX. 1106
`Page 5
`
`

`

`HUMAN ANTI-MURINE IMMUNOGLOBULIN RESPONSES
`
`A
`
`B
`
`175
`
`0'>
`
`:t 150
`3 ., 125
`
`(/)
`
`100
`
`75
`
`50
`
`c
`0
`.,
`a.
`C/)
`a::
`-~
`-s
`..0
`0
`:2> 25
`c
`
`<(
`
`• •••••••••••••••••••••••••••••••••
`
`......... ......... ........ ....... .
`
`175
`
`0'>
`
`:t 150
`3 ., 125
`
`C/)
`
`100
`
`75
`
`50
`
`c
`0
`.,
`5r
`a::
`.£
`-s
`..0
`0
`:2> 25
`c
`
`<(
`
`0
`
`7 .. -
`
`5
`3
`5
`3
`Dose Number
`Dose Number
`Chart 2. Antiglobulin levels in CLL patients. Serum lgG (A) or lgM (8) antibody levels to the T101 antibody are indicated. Points, determinations on serum specimens
`from 9 patients-obtained either prior to therapy (Dose 0) or immediately preceding the indicated dose.
`
`0
`
`7
`
`A
`
`B
`
`t50
`
`Ol
`
`:t 175
`3 t25
`G> .,
`c
`0 a. .,
`
`100
`
`75
`
`I)
`D:
`,!:
`~ 50
`.,Q
`0
`:2> 25
`c <(
`
`.--...
`
`t75
`
`Ol
`
`:t t50
`3 125
`G> .,
`c
`0 a. .,
`I)
`D:
`c
`'5
`.,Q
`0
`~ 25
`c <(
`
`100
`
`75
`
`50
`
`.. --------.... ~' .
`
`....... ............
`- __.- z~=-=-•
`
`....
`
`-
`
`0
`
`3
`5
`Dose Number
`
`7
`
`0
`
`5
`3
`Dose Number
`
`7
`
`Chart 3. Antiglobulin leveis in CTCL patients. Serum lgG (A) or lgM (8) antibody levels to the T1 01 antibody are indicated. Points , determinations on serum specimens
`from patients receiving total T101 doses of 8 (._____....), 66 (e .. . ·• ). 80 (e ---e), or 162 (e -__.) mg. Specimens were obtained either prior to therapy (Dose 0) or
`immediately prior to the indicated dose.
`
`A
`
`B
`
`.--... 175
`
`:t 150
`3 125
`.,
`c
`0 a.
`.,
`.!: -s
`..0
`0
`;Q> 25
`c
`
`0'>
`
`C/)
`
`C/)
`
`0::
`
`<(
`
`100
`
`75
`
`50
`
`175
`
`0'.
`
`:t 150
`3 125
`.,
`C/) c
`0
`a.
`1/) .,
`.£ -s
`..0
`0
`:2> 25
`c <(
`
`100
`
`D:
`
`75
`
`50
`
`. ---- --- -- -- --- -------.. -
`-·
`.. ~-;:~-. ...... ..::-:~::-,,. . ..
`~------
`
`Pre
`
`100
`50
`10
`200
`9.2.27 Antibody Dose (mg)
`
`500
`
`,.
`
`..
`
`Pre
`
`200
`100
`50
`10
`9.2.27 Antibody Dose (mg)
`
`500
`
`Chart4. Antiglobulin levels in melanoma patients. Serum lgG (A) or lgM (8) antibody levels to the 9.2.27 antibody are indicated. Points , determinations on serum
`specimens from 9 patients obtained either prior to therapy (Pre) or immediately preceding the indicated dose. Points from the 3 patients with significant (>2 S.D. above
`mean of normal controls) responses are connected to indicate the progression of the response .
`
`CANCER RESEARCH VOL. 45 FEBRUARY 1985
`882
`
`BIOEPIS EX. 1106
`Page 6
`
`

`

`Antibody
`preparation
`
`T101
`lgG
`lgM
`T101 Fab
`lgG
`lgM
`9. 2. 27
`lgG
`lgM
`9 2. 27 F(ab' ).
`lgG
`lgM
`rAOPC-21 ('Y 1)
`lgG
`lgM
`RPC-5 (1·2a)
`lgG
`lgM
`UPC-1 0 ('Y2a)
`lgG
`lgM
`MOPC-141 (-y 2b)
`lgG
`lgM
`FLOPC-21 ('Y3)
`lgG
`lgM
`ouse lgG
`lgG
`lgM
`Mouse lgM
`lgG
`lgM
`Rabbit lgG
`lgG
`lgM
`• NO. not done.
`
`1.9
`0
`
`1.9
`0.5
`
`2.7
`1.2
`
`111 .8
`1.6
`
`55.9
`6.4
`
`75.0
`6.3
`
`NO
`NO
`
`NO
`NO
`
`NO
`NO
`
`150.9
`2.3
`
`77.9
`8.2
`
`61 .3
`7.5
`
`77 .9
`82
`
`150.9
`2.3
`
`61.3
`7.5
`;
`184.2 104.2 104.2
`5.7
`4.8
`1.2
`
`165.2 180.4 148.0
`11 .1
`2.2
`9.1
`
`185.6 142.4 142.4
`3.6
`1.9
`3.4
`
`1.5
`2.7
`
`17.9
`6.8
`
`NO
`NO
`
`51 .4
`5.3
`
`51 .4
`5.3
`
`19.8
`2.6
`
`24.9
`15.2
`
`2.8
`3.3
`
`No•
`NO
`
`NO
`NO
`
`NO
`NO
`
`25.1 129.4 108.7
`27.8 189.0
`29.1
`
`1.9 109.5
`4.7 125.7
`
`127.6 236.9
`14.8 167.3
`
`1.9
`12.0
`
`20.8
`36.4
`
`127.6 236.9 100.8
`14.8 167.3
`22.2
`
`85.8 256.7 158.6
`13.4
`12.8
`53.4
`
`116.2 173.3
`70.4 162.8
`
`166.7
`159.1
`182.7 228.8
`
`29.2
`0.7
`
`33.1
`6.2
`
`41 .7
`6.7
`
`38.2
`8.5
`
`108.4 297 .5
`103.2 213.5
`
`1.1
`0
`
`1.1
`0.9
`
`0
`0
`
`0
`0.8
`
`0
`0.5
`
`1.1
`1.6
`
`1.5
`0.7
`
`1.7
`3.7
`
`1.9
`1.0
`
`82.2
`13.5
`
`3.1
`29.2
`
`68.5
`59.9
`
`73.4
`12.8
`
`50.1
`12.0
`
`62.9
`75.2
`
`1.5
`1.2
`
`12.1
`17.7
`
`H. B.
`
`W.F.
`
`J.T.
`
`J.S.
`
`c.s.
`
`100
`
`BO
`
`§ 60
`:E
`f
`~ ~ 0
`(,)
`~
`Q.
`
`20
`
`Inhibitor
`Chart 5. Inhibition of human serum lgG antiglobulin activity with soluble murine
`lgG2a monoclonal antibody preparations. Specimens obtained prior to antibody
`therapy (D) or immediately prior to the final dose of antibody (II) were assessed by
`solid-phase ELISA for antiglobulin activity against the antibody used in therapy
`(T1 01 or 9.2.27). Inhibition of binding of serum antibody to the solid-phase antigen
`was assessed following addition of a 1 000-fold excess of the following lgG2a
`murine monoclonal antibodies: 9.2.27 (A); T101 (8); 03 (C); or RPC-5 (0). Results
`are expressed as the percentage of inhibition of titer in the presence of each
`blocking antibody as compared to the titer in the absence of a blocking antibody.
`The patient initials corresponding to those in Table 4 are indicated over each
`distribution.
`
`sented in Table 4, indicate that this patient developed an anti(cid:173)
`globulin response which, although not completely specific for the
`9.2.27 antibody, consisted of a substantial component which
`appears to be specific for the 9.2.27 antibody.
`In order to determine the specificity of the preexisting antiglob(cid:173)
`ulin in these patients, pretreatment sera from 3 of the CTCL
`patients and the 3 melanoma patients with elevated antiglobulin
`levels during therapy were examined for reactivity against the
`panel of mouse and rabbit immunoglobulin preparations indicated
`in Table 4. These analyses demonstrated that the specificity of
`preexisting antiglobulins was very broad, consistent with the
`broad specificity of posttherapy antiglobulins in these patients.
`Data from a representativ

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket